Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + paclitaxel + pegylated liposomal doxorubicin
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of three agents: - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication and transcription by cross-linking DNA strands, leading to cell death. - **Paclitaxel** is a taxane that stabilizes microtubules and inhibits their disassembly, thereby blocking cell division during mitosis. - **Pegylated liposomal doxorubicin** is an anthracycline antibiotic encapsulated in liposomes with polyethylene glycol (PEG), which enhances drug delivery to tumors while reducing cardiotoxicity. Doxorubicin intercalates into DNA and inhibits topoisomerase II, preventing DNA replication and repair. This combination targets rapidly dividing cancer cells through multiple mechanisms—DNA damage (cyclophosphamide, doxorubicin), inhibition of mitosis (paclitaxel), and enhanced tumor targeting/reduced toxicity via the pegylated formulation. It has been primarily investigated for breast cancer treatment in adjuvant or neoadjuvant settings.
- Other names
- cyclophosphamidepaclitaxelpegylated liposomal doxorubicin
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + paclitaxel + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + paclitaxel + pegylated liposomal doxorubicin.